NM_006946.4:c.4621G>A
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_006946.4(SPTBN2):c.4621G>A(p.Glu1541Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000875 in 1,599,640 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_006946.4 missense
Scores
Clinical Significance
Conservation
Publications
- autosomal recessive spinocerebellar ataxia 14Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), G2P, Orphanet
- spinocerebellar ataxia type 5Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_006946.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SPTBN2 | NM_006946.4 | MANE Select | c.4621G>A | p.Glu1541Lys | missense | Exon 24 of 38 | NP_008877.2 | ||
| SPTBN2 | NM_001411025.1 | c.4642G>A | p.Glu1548Lys | missense | Exon 22 of 36 | NP_001397954.1 | |||
| SPTBN2 | NM_001437541.1 | c.4621G>A | p.Glu1541Lys | missense | Exon 23 of 37 | NP_001424470.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SPTBN2 | ENST00000533211.6 | TSL:5 MANE Select | c.4621G>A | p.Glu1541Lys | missense | Exon 24 of 38 | ENSP00000432568.1 | ||
| SPTBN2 | ENST00000309996.7 | TSL:1 | c.4621G>A | p.Glu1541Lys | missense | Exon 23 of 37 | ENSP00000311489.2 | ||
| SPTBN2 | ENST00000617502.5 | TSL:5 | c.4642G>A | p.Glu1548Lys | missense | Exon 22 of 36 | ENSP00000482000.2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152248Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000253 AC: 6AN: 237224 AF XY: 0.0000463 show subpopulations
GnomAD4 exome AF: 0.00000829 AC: 12AN: 1447392Hom.: 0 Cov.: 33 AF XY: 0.0000125 AC XY: 9AN XY: 720440 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152248Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74390 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not specified Uncertain:1
Inborn genetic diseases Uncertain:1
The c.4621G>A (p.E1541K) alteration is located in exon 23 (coding exon 22) of the SPTBN2 gene. This alteration results from a G to A substitution at nucleotide position 4621, causing the glutamic acid (E) at amino acid position 1541 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at